GlassScriptPhysician profile
Sara Sussman
NPI 1225456650
$5,812.71
in general payments reported to CMS, 2019-2025
30 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.21 · 2021: $570 · 2022: $687 · 2023: $988 · 2024: $1,439 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,387 · Education: $99.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,387.23 |
| Education | $99.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,378.14 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $957.42 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $748.19 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $420.28 | 2021-2025 | |
| Kaleo, INC. | $412.92 | 2021-2024 | Auvi-Q |
| Novartis Pharmaceuticals Corporation | $356.84 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $354.55 | 2021-2025 | Cuvitru, Eohilia |
| Alk-Abello, INC | $185.49 | 2021-2025 | Grastek, Odactra, Ragwitek |
| Ars Pharmaceuticals Operations, INC. | $171.17 | 2025 | Neffy |
| Lilly USA, LLC | $161.39 | 2024-2025 | Ebglyss |
| Amgen INC. | $126.48 | 2023-2025 | Tezspire |
| Phadia US INC. | $66.71 | 2021-2025 | Immunocap |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.19 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $48.31 | 2022 | |
| Genentech USA, INC. | $40.51 | 2024-2025 | Xolair |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $40.32 | 2025 | Alvesco |
| Incyte Corporation | $37.08 | 2021-2025 | Opzelura |
| Philips North America LLC | $32.19 | 2025 | Vest Therapy Und |
| Biocryst US Sales Co., LLC | $25.17 | 2025 | Orladeyo |
| Verona Pharma, INC. | $22.11 | 2025 | Ohtuvayre |
| Organon LLC | $21.52 | 2025 | Vtama |
| Pharming Healthcare, INC. | $20.94 | 2025 | Ruconest |
| Aimmune Therapeutics, INC. | $18.60 | 2022 | |
| X4 Pharmaceuticals, INC. | $18.26 | 2024 | Xolremdi |
| Aytu Biopharma, INC. | $18.21 | 2022 | |
| Csl Behring | $17.16 | 2019 | |
| Merck Sharp & Dohme LLC | $16.64 | 2021 | |
| Shire North American Group INC | $16.60 | 2019 | |
| Grifols USA, LLC | $15.96 | 2019 | |
| Pfizer INC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Sussman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.